Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease.

Patel SR, Mailloux LM, Coppola JT, Mindrescu C, Staniloae CS.

Coron Artery Dis. 2008 Aug;19(5):349-53. doi: 10.1097/MCA.0b013e3282fd5c37.

PMID:
18580598
2.

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

Martens FM, Visseren FL, de Koning EJ, Rabelink TJ.

J Cardiovasc Pharmacol. 2005 Dec;46(6):773-8.

PMID:
16306801
3.

Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.

Barac A, Campia U, Matuskey LA, Lu L, Panza JA.

Am J Cardiol. 2008 Apr 1;101(7):980-5. doi: 10.1016/j.amjcard.2007.11.058.

PMID:
18359318
4.

Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.

Rudofsky G Jr, Reismann P, Grafe IA, Konrade I, Djuric Z, Tafel J, Buchbinder S, Zorn M, Humpert PM, Hamann A, Morcos M, Nawroth PP, Bierhaus A.

Horm Metab Res. 2007 Sep;39(9):665-71.

PMID:
17846974
5.

Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians.

Raji A, Gerhard-Herman MD, Williams JS, O'connor ME, Simonson DC.

Diabet Med. 2006 May;23(5):537-43.

PMID:
16681563
6.
7.

Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus.

Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, Hsieh IC, Wang SY, Hung A, Cherng WJ.

Am Heart J. 2006 Dec;152(6):1051.e1-8.

PMID:
17161050
8.

Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone.

Suzuki M, Takamisawa I, Yoshimasa Y, Harano Y.

Diabetes Res Clin Pract. 2007 Apr;76(1):12-7. Epub 2006 Sep 27.

PMID:
17007957
10.

Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase.

Chen H, Ren JY, Xing Y, Zhang WL, Liu X, Wu P, Wang RJ, Luo Y.

Int J Cardiol. 2009 Jan 24;131(3):313-20. doi: 10.1016/j.ijcard.2007.10.044. Epub 2008 Jan 24.

PMID:
18221806
11.

Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension.

Schneider F, Vossler S, Franke S, Bär F, Konrad T.

Int J Clin Pharmacol Ther. 2009 May;47(5):311-20.

PMID:
19473593
12.

Aged garlic extract improves endothelial function in men with coronary artery disease.

Williams MJ, Sutherland WH, McCormick MP, Yeoman DJ, de Jong SA.

Phytother Res. 2005 Apr;19(4):314-9.

PMID:
16041725
13.

Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.

Chiang KH, Huang PH, Huang SS, Wu TC, Chen JW, Lin SJ.

Coron Artery Dis. 2009 Jun;20(4):267-73. doi: 10.1097/MCA.0b013e32832c459c.

PMID:
19440065
15.

Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.

Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M.

Metabolism. 2007 Apr;56(4):491-6.

PMID:
17379006
16.

TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.

Martens FM, Rabelink TJ, op 't Roodt J, de Koning EJ, Visseren FL.

Eur Heart J. 2006 Jul;27(13):1605-9. Epub 2006 Jun 8.

PMID:
16762982
17.

Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.

Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T.

Metabolism. 2007 Apr;56(4):451-8.

PMID:
17378999
18.

The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus.

Nishio K, Shigemitsu M, Kodama Y, Itoh S, Konno N, Satoh R, Katagiri T, Kobayashi Y.

J Cardiometab Syndr. 2008 Fall;3(4):200-4. doi: 10.1111/j.1559-4572.2008.00019.x.

19.

Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients.

Hiramatsu S, Tajiri Y, Karashima T.

Diabetes Obes Metab. 2004 May;6(3):231-3.

PMID:
15056132
20.

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.

Forst T, Hohberg C, Fuellert SD, Lübben G, Konrad T, Löbig M, Weber MM, Sachara C, Gottschall V, Pfützner A.

Horm Metab Res. 2005 Aug;37(8):521-7.

PMID:
16138267

Supplemental Content

Support Center